Urology
Volume 72, Issue 2 , Pages 247-254 , August 2008

Prostate Tissue Androgens: History and Current Clinical Relevance

  • Leonard S. Marks

      Affiliations

    • Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California
    • Urological Sciences Research Foundation, Culver City, California
    • Corresponding Author InformationReprint requests: Leonard S. Marks, M.D., Urological Sciences Research Foundation, Culver Medical Plaza, 3831 Hughes Avenue, Suite 501, Culver City, CA 90232.
    • ,
  • Elahe A. Mostaghel

      Affiliations

    • Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Peter S. Nelson

      Affiliations

    • Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington

Received 24 January 2008 ,Accepted 25 March 2008.

References 

  1. Heracek J, Richard H, Martin H, et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids. 2007;72:375–380
  2. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351–2361
  3. Mohler JL, Gregory CW, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10:440–448
  4. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960;39:1157–1175
  5. Albert J, Geller J, Geller S, et al. Prostate concentrations of endogenous androgens by radioimmunoassay. J Steroid Biochem. 1976;7:301–307
  6. Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem. 1968;243:5953–5960
  7. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213–1215
  8. Walsh PC, Hutchins GM, Ewing LL. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J Clin Invest. 1983;72:1772–1777
  9. Gormley GJ, Stoner E, Bruskewitz RC, et al. Finasteride Study Group The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185–1191
  10. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  11. Mohler JL, Gaston KE, Moore DT, et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol. 2004;171:2277–2280
  12. Osegbe DN, Ogunlewe JO. Androgen concentration in blacks with benign and malignant prostatic disease. J Urol. 1988;140:160–164
  13. Marks LS, Hess DL, Dorey FJ, et al. Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. Urology. 2006;68:337–341
  14. Siiteri PK, Wilson JD. Dihydrotestosterone in prostatic hypertrophy (I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man). J Clin Invest. 1970;49:1737–1745
  15. Salerno R, Moneti G, Forti G, et al. Simultaneous determination of testosterone, dihydrotestosterone and 5 alpha-androstan-3 alpha,-17 beta-diol by isotopic dilution mass spectrometry in plasma and prostatic tissue of patients affected by benign prostatic hyperplasia: effects of 3-month treatment with a GnRH analog. J Androl. 1988;9:234–240
  16. Forti G, Salerno R, Moneti G, et al. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J Clin Endocrinol Metab. 1989;68:461–468
  17. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74:505–508
  18. Shibata Y, Ito K, Suzuki K, et al. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate. 2000;42:45–55
  19. Wurzel R, Ray P, Major-Walker K, et al. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007;10:149–154
  20. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006;91:3850–3856
  21. Geller J, Albert J, Lopez D, et al. Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate. J Clin Endocrinol Metab. 1976;43:686–688
  22. Krieg M, Bartsch W, Janssen W, et al. A comparative study of binding, metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostate. J Steroid Biochem. 1979;11:615–624
  23. Roehrborn CG, McConnell JD. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In:  Wein AJ,  Kavoussi LR,  Novick AC, et al. editor. Campbell-Walsh Urology. vol XVI:Philadelphia: WB Saunders; 2007;p. 2727–2738
  24. Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004;172:915–919
  25. Gleave M, Qian J, Andreou C, et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer—results from a 4-month pre-radical prostatectomy study. Prostate. 2006;66:1674–1685
  26. Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol. 2006;176:1299–1306
  27. Marks LS, Hess DL, Dorey FJ, et al. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology. 2001;57:999–1005
  28. Lazier CB, Thomas LN, Douglas RC, et al. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate. 2004;58:130–144
  29. Iczkowski KA, Qiu J, Qian J, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology. 2005;65:76–82
  30. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005;63:231–239
  31. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172:1314–1317
  32. Geller J, Albert JD, Nachtsheim DA, et al. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol. 1984;132:693–696
  33. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10:7121–7126
  34. Weber JP, Oesterling JE, Peters CA, et al. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol. 1989;141:987–992
  35. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67:5033–5041
  36. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217–227
  37. Mizokami A, Koh E, Fujita H, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 2004;64:765–771
  38. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815–2825
  39. Suzuki K, Nishiyama T, Hara N, et al. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis. 2007;10:301–306
  40. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96:1241–1246
  41. Long BJ, Grigoryev DN, Nnane IP, et al. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res. 2000;60:6630–6640
  42. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253–8261
  43. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482–492
  44. Fowler JE, Whitmore WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126:372–375
  45. Johnson DE, Haynie TP. Phosphorus-32 for intractable pain in carcinoma of prostate: analysis of androgen priming, parathormone rebound, and combination therapy. Urology. 1977;9:137–139
  46. Gaylis FD, Lin DW, Ignatoff JM, et al. Prostate cancer in men using testosterone supplementation. J Urol. 2005;174:534–538
  47. Dreifus C. A Conversation with Andrew von Eschenbach: Director Tries to Untangle Web of Cancer Controversies, Science Section. New York Times. March 11, 2003.
  48. Bhasin S, Singh AB, Mac RP, et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24:299–311
  49. Liverman CT, Blazer DG. Testosterone and Aging: Clinical Research Directions. In: Washington, DC: National Academies Press; 2004;p. 219
  50. Bruun E, Frandsen H, Nielsen K, et al. Dihydrotestosterone measured in core biopsies from prostatic tissues. Am J Clin Oncol. 1988;11(suppl 2):S27–S29
  51. Higashi T, Yamauchi A, Shimada K, et al. Determination of prostatic androgens in 10 mg of tissue using liquid chromatography-tandem mass spectrometry with charged derivatization. Anal Bioanal Chem. 2005;382:1035–1043
  52. Kalhorn TF, Page ST, Howald WN, et al. Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21:3200–3206
  53. Resko JA, Ellinwood WE, Pasztor LM, et al. Sex steroids in the umbilical circulation of fetal rhesus monkeys from the time of gonadal differentiation. J Clin Endocrinol Metab. 1980;50:900–905
  54. Saad F, Gooren LJ, Haider A, et al. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008;29:102–105
  55. Page ST, Marck BT, Tolliver JM, et al. Tissue selectivity of the anabolic steroid, 19-nor-4-androstenediol-3{beta},17{beta}-diol in male Sprague-Dawley rats: selective stimulation of muscle mass and bone mineral density relative to prostate mass. Endocrinology. 2007;Epub Dec 20

 This work was supported by the Urological Sciences Research Foundation (L.S.M.); a Career Development Award from the Prostate Cancer Foundation, a Young Investigator Award from the American Society of Clinical Oncology, and National Institutes of Health grant K23 CA122820-02 (E.A.M.); and the National Institutes of Health/National Cancer Institute Pacific Northwest Prostate Cancer SPORE grant P50CA97186 (P.S.N.).

PII: S0090-4295(08)00372-5

doi: 10.1016/j.urology.2008.03.033

Urology
Volume 72, Issue 2 , Pages 247-254 , August 2008

Article Tools

* Image Usage & Resolution